netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
Please also refer to the Cancer Drugs Fund list
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
 note  Use in accordance with local guidelines
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene
08.01.05  Expand sub section  Bortezomib to top
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide to top
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds to top
08.01.05  Expand sub section  Procarbazine
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
   
Cabozantinib caps (Cometriq)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE Technology Appraisal guidance (see links below): 

 

 
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
   
Cabozantinib tablets (Cabometyx)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE Technology Appraisal guidance (see links below): 

 

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
   
Crizotinib caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
   
Dasatinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Everolimus tabs (breast cancer and renal cancer)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Approved as per NICE TA guidance (see links below) 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Everolimus tabs (neuroendocrine tumours)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Approved for use in neuroendocrine tumours as per NICE TA449 
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Gefitinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
   
Lenvatinib caps (renal cancer)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE TA guidance (see links below)

 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Nilotinib caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Nintedanib caps (Vargatef)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
   
Osimertinib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
   
Pazopanib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
   
Sorafenib tablets
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Approved as per NICE Technology Appraisal guidance 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
   
Sunitinib caps (neuroendocrine tumours)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Approved for use in neuroendocrine tumours as per NICE TA449 
Link  MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Sunitinib caps (renal cell, and gastrointestinal stromal tumours)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Approved for use in renal cell and gastrointestinal stromal tumours as per NICE TA169 and NICE TA179 
Link  MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
   
Tivozanib caps
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Approved as per NICE TA guidance (see links below)

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
   
Vemurafenib tabs
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
   
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Trabectedin to top
08.01.05  Expand sub section  Trastuzumab
08.01.05  Expand sub section  Tretinoin
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

Amber 1

Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

Amber 2

Specialist initiation followed by maintenance prescribing in primary care  

Amber 3

Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  

Green

Specialist and non-specialist initiation  

Grey

Not recommended for prescribing  

netFormulary